Shingles Vaccine Access Sparks Debate as Availability Limited to Modern 60-Year-Olds
Millions of older adults may miss out on crucial protection against shingles as a new public vaccination program in the Netherlands prioritizes those turning 60, rather than offering it to the broader existing senior population. The decision has prompted criticism from patient advocacy groups who argue it’s an inadequate approach to tackling the increasingly common and painful condition.
Shingles, caused by the reactivation of the varicella-zoster virus (the same virus that causes chickenpox), affects nearly 100,000 people in the Netherlands annually, leading to debilitating pain, itchy blisters, and potential long-term nerve damage. The condition is particularly prevalent among individuals over 60, and its incidence is expected to rise as the population ages.
The announcement of a publicly funded shingles vaccine program was initially welcomed, but the limited rollout has raised concerns. According to ANBO-PCOB, a leading organization for seniors, the current plan is disappointing for those already over 60. “How old do you have to be to be allowed to get sick?” the organization questioned in a recent statement, highlighting the frustration felt by many.
Currently, two vaccines are available against shingles: Shingrix and Zostavax. The Dutch Health Council recommends Shingrix, which prevents nine out of ten cases of shingles and associated long-term pain, and offers lasting protection. The Shingrix vaccine requires two doses, administered two to six months apart, as detailed by the RIVM (National Institute for Public Health and the Environment).
The cost of the vaccine is also a factor for some. Reports indicate a price of around 400 euros for the vaccine, leading some individuals to consider forgoing other expenses to afford it. This financial burden underscores the importance of accessible public health programs.
The debate surrounding vaccine access was recently featured on the Dutch television program Radar on March 2, 2026, where concerns about awareness and affordability were raised. A recent panel survey revealed that over 70% of the public were unaware of the vaccine’s existence. State Secretary Vincent Karremans of Youth, Prevention and Sport responded to questions about the vaccine during the broadcast.
While the Netherlands is now implementing a targeted vaccination program, other countries like Germany and England already offer free shingles vaccinations to older adults. The findings from the RIVM suggest that the Shingrix vaccine is highly effective, preventing around 90% of shingles cases and 90% of long-term pain complications, even six to ten years after vaccination. This level of protection could significantly reduce the burden of this painful condition and improve quality of life for seniors.
The vaccine is also recommended for adults in certain medical risk groups, including those who have undergone stem cell or organ transplants, are undergoing cancer treatment, or have HIV. Even individuals who have previously had shingles can benefit from vaccination to prevent future outbreaks.
